Tesofensine

Overview

Tesofensine is an investigational, orally administered drug that has been studied primarily for weight management. It is a triple monoamine reuptake inhibitor, meaning it acts on three of the brain’s signalling chemicals at once — serotonin, noradrenaline, and dopamine.

It was originally developed by NeuroSearch as a candidate treatment for Parkinson’s and Alzheimer’s disease. Those programs showed limited benefit, but participants consistently lost weight, which prompted researchers to redirect the compound toward obesity.

In a Phase 2 trial, participants taking tesofensine alongside an energy-restricted diet lost roughly 10% of their body weight over 24 weeks — more than placebo. Tesofensine is not approved by the FDA or any major regulator and remains investigational. Unlike many compounds in this reference, it is a small molecule taken by mouth rather than an injectable peptide.

How it works

By blocking the reuptake of serotonin, noradrenaline, and dopamine, tesofensine is thought to raise the levels of these neurotransmitters in the brain. Researchers have proposed that this reduces appetite and increases feelings of fullness, and some studies have also reported a modest increase in energy expenditure and fat oxidation.

Preclinical work suggests the appetite-suppressing effect may involve activity in the hypothalamus, a brain region central to hunger and feeding. The precise mechanism in humans is still being studied, and the evidence base remains limited.

Reported benefits

• Reduced appetite and increased satiety (studied for weight management)
• Body-weight loss when combined with an energy-restricted diet (Phase 2 data)
• Modest increases in energy expenditure and fat oxidation reported in short studies

These are reported findings from research settings, not guaranteed outcomes.

Considerations & side effects

Because tesofensine has not been approved and long-term human data is limited, its full safety profile is not well characterized. Commonly reported side effects in trials include dry mouth, headache, nausea, insomnia, and changes in bowel habits. Studies have also noted dose-dependent increases in heart rate and blood pressure, along with the potential for mood or other psychiatric effects, which is why cardiovascular and psychiatric monitoring has been emphasized in the research.

Product quality in the research-chemical market varies widely, and an investigational compound is not a substitute for evaluation and treatment by a qualified clinician.